Teams link: Join the meeting now

Meeting ID: 277 080 580 861 9

Passcode: nk3a6S6b

Learning Objectives: 

• Describe the epidemiology of HIV transmission and the evolution of pre-exposure prophylaxis (PrEP) in the context of current guideline recommendations and historical barriers to care.

• Describe mechanism of action (MOA), pharmacokinetics, and novel drug delivery mechanism of Yeztugo (lenacapavir). Discuss clinical trial evidence that supported FDA approval.

• Apply an understanding of the clinical, psychosocial, financial, and societal considerations of long-acting injectable HIV PrEP to evaluate its place in therapy and navigate patient access challenges.